Efraim Shek
No más puestos en curso
Perfil
Efraim Shek worked as a Principal at Abbott Laboratories, Cephalon, Inc., and Syntex Corp.
He was also a Senior Vice President-Research & Development at Adamas Pharmaceuticals LLC and a Faculty Member at the University of Florida.
Shek holds a graduate and doctorate degree from the University of Kansas and a graduate degree from The Hebrew University of Jerusalem.
Antiguos cargos conocidos de Efraim Shek.
Empresas | Cargo | Fin |
---|---|---|
University of Florida | Corporate Officer/Principal | - |
ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | - |
Pharmatec, Inc. | Corporate Officer/Principal | - |
Syntex Corp. | Corporate Officer/Principal | - |
Formación de Efraim Shek.
University of Kansas | Doctorate Degree |
The Hebrew University of Jerusalem | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ABBOTT LABORATORIES | Health Technology |
Empresas privadas | 4 |
---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Syntex Corp. | Health Technology |
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Pharmatec, Inc. | Health Technology |
- Bolsa de valores
- Insiders
- Efraim Shek